These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19275550)

  • 21. Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.
    Wei Y; Xu W
    Future Cardiol; 2019 Mar; 15(2):127-133. PubMed ID: 30793928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
    Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
    Hanefeld M; Schaper F
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):153-63. PubMed ID: 18248270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance.
    Kentrup H; Bongers H; Spengler M; Kusenbach G; Skopnik H
    Eur J Pediatr; 1999 Jun; 158(6):455-9. PubMed ID: 10378391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
    Frantz S; Calvillo L; Tillmanns J; Elbing I; Dienesch C; Bischoff H; Ertl G; Bauersachs J
    FASEB J; 2005 Apr; 19(6):591-3. PubMed ID: 15671153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure.
    Shibao C; Gamboa A; Diedrich A; Dossett C; Choi L; Farley G; Biaggioni I
    Hypertension; 2007 Jul; 50(1):54-61. PubMed ID: 17515447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
    Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
    Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the alpha-glucosidase inhibitor acarbose on the development of long-term complications in diabetic animals: pathophysiological and therapeutic implications.
    Creutzfeldt W
    Diabetes Metab Res Rev; 1999; 15(4):289-96. PubMed ID: 10495478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical observation on improving senile postprandial hyperglycemia and insulin sensitivity with combination of acarbose and liuwei nengxiao capsule].
    Yu W; Gao YY; Zhang X
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 May; 24(5):396-9. PubMed ID: 15199620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of α-glucosidase inhibitors to prevent postprandial endothelial dysfunction.
    Kato T; Node K
    Int Heart J; 2014; 55(5):386-90. PubMed ID: 25109946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
    Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
    Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects.
    Rabasa-Lhoret R; Burelle Y; Ducros F; Bourque J; Lavoie C; Massicotte D; Péronnet F; Chiasson JL
    Diabet Med; 2001 Sep; 18(9):739-44. PubMed ID: 11606172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes.
    Breuer HW
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):421-40. PubMed ID: 14703948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the potential of acarbose to reduce cardiovascular disease.
    Standl E; Theodorakis MJ; Erbach M; Schnell O; Tuomilehto J
    Cardiovasc Diabetol; 2014 Apr; 13():81. PubMed ID: 24742256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
    Kitaoka H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.